Category: Asean

CEO of family company Angelini Industries will also lead the pharmaceutical company from today, bringing strong leadership experience and strategic vision

ROME, Jan. 21, 2026 (GLOBE NEWSWIRE) — Angelini Pharma, part of the multinational privately owned industrial group Angelini Industries, today announced the appointment of Sergio Marullo di Condojanni as Chief Executive Officer. He has served as CEO of Angelini Industries since 2020 and will maintain that role while assuming leadership of the pharmaceutical division to drive cohesive strategy implementation, leveraging extensive executive, governance, and financial expertise. Jacopo Andreose, who led Angelini Pharma until the end of 2025, will become a member of the Angelini Holding board and a senior advisor to the Angelini Pharma board.

The appointment is part of Angelini Industries’ multi-year effort to strengthen its corporate governance and operating model, building on the Group’s century-long heritage of pharmaceutical excellence. The transition aims to further solidify pharmaceutical healthcare as a core pillar of its long-term growth strategy alongside industrial technology.

Thea Paola Angelini, Chair of Angelini Holding and majority shareholder, stated:
“Appointing Sergio as CEO will drive simplified decision-making for our pharmaceutical business — the heart of our Group. This strategic choice will enable us to be closer to market needs and, above all, to patients, by delivering greater efficiency, agility, faster decision-making, and flexibility.”

Marullo di Condojanni’s dual role will enable him to directly spearhead strategy implementation within the healthcare division, seeking to maximize the value of Angelini Pharma in a high-growth sector. He will focus on further elevating the company’s leadership in Brain Health, with particular attention to rare neurological diseases, while continuing to build on its legacy in Consumer Healthcare. He will also prioritize expanding Angelini Pharma’s global reach, including additional acquisitions to strengthen its pipeline of innovative medicines and promising candidates. The emphasis remains on sustaining investment in research, development, and manufacturing operations in Italy, while simultaneously turning outwardly for commercial expansion opportunities on the international scale.

“I am excited and deeply honored to take on this important role at the helm of Angelini Pharma during a pivotal moment of transformation,” said Sergio Marullo di Condojanni. “Our strategic priorities are clear: strengthen long-term competitiveness and seize transformative M&A opportunities that will enable us to scale globally. At the same time, our focus will be on driving our ambitious strategy to achieve market leadership and deliver breakthrough solutions in brain health for patients worldwide.”

As Angelini Industries’ CEO, Sergio Marullo di Condojanni oversaw record revenue growth, expanding the Group to 21 countries and €1.6 billion* in revenue, and successfully launched Angelini Ventures, the Group’s €300 million corporate venture capital dedicated to biotech and medtech. Prior to Angelini Industries, his extensive background included influential roles in the Italian financial sector, such as Chairman of the Territorial Committee of Banco BPM, and a key appointment to the Advisory Board of the G20 Business Summit Italy 2021. He holds a Ph.D. in Domestic and International Arbitration, is a Full Professor of Private Law, and serves on the Board of Directors for institutions including the Fondazione Istituto Italiano di Tecnologia.

Under his leadership, Angelini Pharma will accelerate its strategy to become a global leader in Brain Health. The company has significantly strengthened its pipeline, diversifying into innovative therapeutic modalities that include small molecules, biologics, and anti-sense oligonucleotides. Most recently, Angelini Pharma signed an exclusive option agreement with Sovargen for the antisense oligonucleotide SVG1051 in September 2025. Other recent strategic deals include the May 2025 collaboration announcement with GRIN Therapeutics for the investigational drug radiprodil, and rights secured for OmniAb’s preclinical asset RO’599. Further reinforcing the pipeline are a partnership with Cureverse for the Nrf2-targeting compound CV-01 (since 2024), and a collaboration with JCR Pharmaceuticals, which leverages their proprietary J-Brain Cargo^® technology to develop novel brain-penetrant biologic therapies for epilepsy (since 2023).

The new strategic vision will be supported by a new organizational structure that establishes dedicated franchises aiming to maximize value creation and support international expansion into high-growth regions.

About Brain Health
Brain health as a therapeutic area includes both neurological and mental health conditions.¹ Brain health is defined by the World Health Organization as a state of brain functioning across cognitive, sensory, social-emotional, behavioral and motor domains, allowing a person to realize their full potential over the course of their life, irrespective of the presence or absence of disorders.²

Brain health represents an urgent global health priority. An estimated 179 million Europeans are living with brain health conditions³ and more than 18% of all health loss around the world is associated with brain conditions.⁴ Additionally, brain health conditions are responsible for considerable individual, economic and societal impact, including loss of independence, reduced productivity, strained relationships, increased risk of suicide as well as high healthcare costs.⁵ There is an urgent need to raise awareness, and reduce stigma, prejudice and discrimination, to ensure that brain health is valued, promoted and protected for all.²

About Epilepsy

Epilepsy is one of the most widespread neurological diseases in the world, affecting globally approximately 50 million people of all ages.⁶ In Europe, up to six million people are estimated to be living with this disease.⁷ Epilepsy can have multiple potential causes, including structural, metabolic, genetic and other factors, though approximately half of cases worldwide do not have a known cause.⁶

The complications associated with epilepsy are severe, with a risk of premature mortality up to three times higher than the general population.⁶ The recurrent seizures associated with this condition also have wide-ranging effects on a person’s broader physical and mental health, education and employment opportunities and other quality of life factors.⁶

Treatments are available to help reduce seizures and improve quality of life, however approximately 40% of people living with epilepsy are still uncontrolled despite the treatment with two anti-seizure medications.⁸

About Angelini Pharma
Angelini Pharma is an international pharmaceutical company, part of the privately owned multi-business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20^th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. For more information about Angelini Pharma please visit: https://www.angelinipharma.com.

About Angelini Industries
Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, it represents a solid and diversified industrial entity employing around 5,600 people operating in 21 countries worldwide, with revenues of €1.6 billion. Angelini Industries operates in the Health, Industrial Technology and Consumer Goods sectors. Led by the Angelini family for over 100 years, the industrial group is distinguished by an investment strategy focused on growth, a governance model that combines the long-term vision of family-owned businesses with the practices of publicly listed companies, in-depth knowledge of markets and business sectors, and a commitment to promoting sustainable growth for people, communities, ecosystems, and the planet. To learn more, please visit www.angeliniindustries.com.

Contact
Chiara Antoniucci
Global Head of Brand and Media Communications, Angelini Pharma
+39 3477133926
[email protected]

^{______________________________}

*According to International Financial Reporting Standards (IFRS) for the fiscal year ending December 31, 2024

¹ Winkler AS, et al. Lancet Glob Health. 2024;12(5):e735-e736.
² World Health Organization. Optimizing brain health across the life course: WHO position paper. Geneva: World Health Organization; 2022.
³ Nutt D, et al. Eurohealth (Int) 2017;23:21–5.
⁴ Institute for Health Metrics and Evaluation. Understanding brain health around the world. Available at: https://brainhealthatlas.org/. Accessed November 2025.
⁵ World Health Organization. World mental health report: transforming mental health for all. Geneva: World Health Organization; 2022.
⁶ World Health Organization. “Epilepsy Key Facts.” N.p., 9 Feb. 2023. Web. 24 Aug. 2023.
⁷ Behr et al. Epidemiology of epilepsy. Revue Neurologique 2016 Jan; 172(1):27-36.
⁸ Chen Z, et al. JAMA Neurol. 2018 Mar 1;75(3):279-286.

MAT-UKI-0398-NP | December 2025

GlobeNewswire Distribution ID 1001160222

SLOUGH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) — John Crane, a global leader in flow-control technologies and an innovator in solutions for rotating equipment, and a business of Smiths Group plc, is marking 50 years since a breakthrough that revolutionised gas compression sealing. In 1976, the introduction of the Type 28 dry gas seal transformed compressor reliability and set a new global benchmark for sealing performance, safety and efficiency.

While pioneering work on non-contacting spiral-groove technology began in 1968, and the first commercially installation was achieved in 1975, it was the introduction of the Type 28 dry gas seal in 1976 that created a true turning point for the industry. Since then, dry gas seals have become essential components in centrifugal compressors across applications such as oil and gas, petrochemicals, power generation and, increasingly, hydrogen and carbon-capture applications.

Over the past five decades, continuous innovation has extended sealing performance into new pressures, temperatures and operating conditions. Advances have included bi-directional grooves, ultra-high-pressure capability up to 425 barg / 6164 psig, new materials such as Carbon LF and digital diagnostics made possible through John Crane Sense^® Turbo, enabling real-time condition monitoring and predictive insights.

Sustainability has also become a defining element of sealing technology. Wet-to-dry gas seal retrofit programmes have delivered CO₂ reductions of around 278,000 tonnes per year in certain customer applications, while modern dry gas seals can reduce methane and fugitive emissions by up to 95% when replacing traditional oil-lubricated wet seals. The latest separation seal designs, such as the Type 93AX further reduces nitrogen consumption by up to 80% compared to traditional carbon ring assemblies, supporting operators’ energy efficiency goals.

Today, John Crane’s dry gas seals support a global installed base numbering in the thousands, backed by over 200 manufacturing, sales and service centres, including 12 turbo service centres worldwide. This combination of technology leadership, global reach and on-site expertise continues to support customers’ operational reliability, environmental performance and safety goals.

“Dry gas seals transformed compressor reliability and set a new industry standard in 1976,” said Rubén Álvarez, President of John Crane. “Our 50-year anniversary not only celebrates a milestone in engineering innovation but also recognises the continued dedication of our global teams and the customers who have trusted our technology for decades. We remain committed to advancing sealing solutions that support reliability, efficiency and the future of sustainable energy.”

Throughout 2026, John Crane will mark the anniversary with the release of technical papers, global customer stories, historical reflections, and multimedia content celebrating the evolution of dry gas seal technology from its pioneering origins to today’s advanced sealing solutions engineered for the next generation of energy.

About John Crane
John Crane is a global leader in flow-control technologies and an innovator in solutions for rotating equipment in the energy and process industries. Our portfolio spans mechanical seals, systems, couplings and filtration systems, supported by advanced service solutions and digital diagnostics. With over 200 service, sales and manufacturing centres across 50 countries, John Crane is an integral pillar of Smiths Group plc, a FTSE 100 industrial technology company dedicated to engineering a better future.

Learn more at www.johncrane.com.

Contact: William Lowden: [email protected]

GlobeNewswire Distribution ID 9627913

FORT WASHINGTON, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) — Coventry, the leader and creator of the secondary market for life insurance, today announced that Reid Buerger, its CEO, has been recognized by Finseca as a 2025 ID Twenty Award recipient. The award was presented at NAILBA 44, honoring the top innovators and industry-shaping leaders in independent distribution.

Finseca’s ID Twenty Award spotlights twenty professionals each year whose achievements materially advance the insurance community. Recognition is considered one of the most significant distinctions in the field, reserved for those driving measurable impact across distribution, product development, and client outcomes.

Buerger’s selection reflects his continued leadership in shaping modern longevity and life insurance markets, as well as Coventry’s ongoing work to expand secondary market access, opportunity, and value across the independent distribution ecosystem.

“This recognition reflects the work our team at Coventry continues to do to expand the secondary market for life insurance,” said Reid Buerger, CEO of Coventry. “Independent distribution plays an important role in helping policyowners understand their options, and we remain focused on building market structures that support choice, value, and long-term outcomes.”

About Coventry
Coventry is the leader and creator of the secondary market for life insurance. For more than 20 years, we have been driving the industry forward and expanding opportunities for life insurance policyowners. Coventry’s deep experience combined with a fierce commitment to consumer rights makes Coventry the clear market leader, a position we use to raise industry standards and expand consumer choice. To date, we have delivered more than $6 billion to policyowners who no longer have a need for their policies. To learn more about Coventry, please visit Coventry.com.

Media Contact:
Jonny Shiver
Vice President, Marketing
(877) 836-8300

GlobeNewswire Distribution ID 9627455

SLOUGH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) — John Crane, a global leader in flow-control technologies and an innovator in solutions for rotating equipment, and a business of Smiths Group plc, is marking 50 years since a breakthrough that revolutionised gas compression sealing. In 1976, the introduction of the Type 28 dry gas seal transformed compressor reliability and set a new global benchmark for sealing performance, safety and efficiency.

While pioneering work on non-contacting spiral-groove technology began in 1968, and the first commercially installation was achieved in 1975, it was the introduction of the Type 28 dry gas seal in 1976 that created a true turning point for the industry. Since then, dry gas seals have become essential components in centrifugal compressors across applications such as oil and gas, petrochemicals, power generation and, increasingly, hydrogen and carbon-capture applications.

Over the past five decades, continuous innovation has extended sealing performance into new pressures, temperatures and operating conditions. Advances have included bi-directional grooves, ultra-high-pressure capability up to 425 barg / 6164 psig, new materials such as Carbon LF and digital diagnostics made possible through John Crane Sense^® Turbo, enabling real-time condition monitoring and predictive insights.

Sustainability has also become a defining element of sealing technology. Wet-to-dry gas seal retrofit programmes have delivered CO₂ reductions of around 278,000 tonnes per year in certain customer applications, while modern dry gas seals can reduce methane and fugitive emissions by up to 95% when replacing traditional oil-lubricated wet seals. The latest separation seal designs, such as the Type 93AX further reduces nitrogen consumption by up to 80% compared to traditional carbon ring assemblies, supporting operators’ energy efficiency goals.

Today, John Crane’s dry gas seals support a global installed base numbering in the thousands, backed by over 200 manufacturing, sales and service centres, including 12 turbo service centres worldwide. This combination of technology leadership, global reach and on-site expertise continues to support customers’ operational reliability, environmental performance and safety goals.

“Dry gas seals transformed compressor reliability and set a new industry standard in 1976,” said Rubén Álvarez, President of John Crane. “Our 50-year anniversary not only celebrates a milestone in engineering innovation but also recognises the continued dedication of our global teams and the customers who have trusted our technology for decades. We remain committed to advancing sealing solutions that support reliability, efficiency and the future of sustainable energy.”

Throughout 2026, John Crane will mark the anniversary with the release of technical papers, global customer stories, historical reflections, and multimedia content celebrating the evolution of dry gas seal technology from its pioneering origins to today’s advanced sealing solutions engineered for the next generation of energy.

About John Crane
John Crane is a global leader in flow-control technologies and an innovator in solutions for rotating equipment in the energy and process industries. Our portfolio spans mechanical seals, systems, couplings and filtration systems, supported by advanced service solutions and digital diagnostics. With over 200 service, sales and manufacturing centres across 50 countries, John Crane is an integral pillar of Smiths Group plc, a FTSE 100 industrial technology company dedicated to engineering a better future.

Learn more at www.johncrane.com.

Contact: William Lowden: [email protected]

GlobeNewswire Distribution ID 9627913

CGTN published an article on Chinese President Xi Jinping’s meeting with Canadian Prime Minister Mark Carney. Centered on the development of bilateral relations, the article highlighted that the two countries share broad prospects for cooperation, and explored how China and Canada are committed to promoting the steady, solid and sound development of bilateral ties under the new circumstances.

BEIJING, Jan. 17, 2026 (GLOBE NEWSWIRE) — Last year, a total of 125 Canadian companies participated at the 8th China International Import Expo, the world’s first national-level exposition dedicated to imports, in east China’s Shanghai, marking a record-high Canadian presence.

Based on mutual benefit and win-win cooperation, China and Canada share broad prospects for cooperation in fields such as trade, energy, agriculture and forestry, green technology and tourism.

During Canadian Prime Minister Mark Carney’s visit to China, which he started on Wednesday, the two countries signed multiple cooperation documents covering trade, customs, energy, construction, culture and public security, pledging to deepen cooperation in diverse sectors of mutual interest.

On Friday, Chinese President Xi Jinping met with Carney in Beijing, emphasizing that the healthy and stable development of China-Canada relations is in the common interests of the two countries and also conducive to world peace, stability, development and prosperity.

Promoting healthy, stable, sustainable China-Canada ties

During the meeting, Xi called on China and Canada to advance the building of a new strategic partnership with a sense of responsibility toward history, the people and the world.

Through the joint efforts of both sides, China-Canada relations have shown positive momentum toward recovery and improvement since last year.

In October 2025, the leaders of the two countries met on the sidelines of the 32nd Asia-Pacific Economic Cooperation (APEC) Economic Leaders’ Meeting in South Korea, with both sides agreeing to resume exchanges and cooperation in various fields, promote the resolution of specific economic and trade issues of mutual concern, and jointly advance the development of the China-Canada strategic partnership.

The engagement was preceded by a meeting between Chinese Premier Li Qiang and Carney on the sidelines of the United Nations General Assembly a month earlier, followed by visits to China by senior Canadian officials, including the foreign minister.

As a gesture of goodwill, China resumed group tour services for Chinese citizens traveling to Canada through travel agencies in November, aiming to further enhance people-to-people exchanges between the two countries and foster mutual understanding and friendship between the two peoples.

Noting that China and Canada enjoy extensive common interests and opportunities, Carney said Canada is willing to work with China to build a new strategic partnership that is strong and enduring so as to deliver greater benefits to the two peoples.

Partners of common development and collaboration

Xi put forward four proposals regarding China-Canada relations – both countries should be partners in common development and collaboration featuring mutual respect and mutual trust.

The essence of China-Canada economic and trade relations is mutual benefit and win-win cooperation, with both sides benefiting from cooperation, Xi underscored, adding that China’s high-quality development and high-level opening up will continue to provide new opportunities and expand new space for China-Canada cooperation.

Economically, China and Canada remain deeply complementary. China has long been Canada’s second-largest trading partner, second-largest source of imports, and second-largest export market.

Canada exports energy products, agricultural commodities, minerals, and wood pulp, while China supplies machinery, consumer goods, electronics, and intermediate industrial inputs essential to Canadian manufacturing.

Canada possesses technological advantages in areas such as clean energy, biomanufacturing and agricultural technology, which align closely with China’s industrial upgrading needs. The “technology + market” model is emerging as a new paradigm for China-Canada cooperation.

In a joint statement released following the meeting of the two leaders, China and Canada voiced their commitment to expanding bilateral trade, strengthening two-way investment, and deepening cooperation in diverse sectors of mutual interest.

The two sides reaffirmed the importance of a fair and open business environment for enterprises of both countries, and committed to addressing economic and trade issues of mutual concern through constructive consultation, including through a renewed China-Canada Joint Economic and Trade Commission.

Xi called on both sides to increase efforts to promote cooperation and reduce the negative list, thereby strengthening the bond of shared interests through deeper and broader cooperation.

For more information, please click:
https://news.cgtn.com/news/2026-01-16/How-China-Canada-promote-steady-solid-development-of-bilateral-ties-1JYU4eePiBW/p.html

Contact: CGTN
[email protected]

GlobeNewswire Distribution ID 9627513